These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6149015)

  • 1. Glutamic acid modification of vincristine toxicity.
    Jackson DV; Rosenbaum DL; Carlisle LJ; Long TR; Wells HB; Spurr CL
    Cancer Biochem Biophys; 1984 Sep; 7(3):245-52. PubMed ID: 6149015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination vincristine and VP-16-213: evaluation of drug sequence.
    Jackson DV; Long TR; Rice DG; Morgan TM
    Cancer Biochem Biophys; 1986 Oct; 8(4):265-75. PubMed ID: 3802048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
    Chello PL; Sirotnak FM
    Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study.
    Mokhtar GM; Shaaban SY; Elbarbary NS; Fayed WA
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):594-600. PubMed ID: 20921909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.
    Avramis VI; Plunkett W
    Cancer Res; 1982 Jul; 42(7):2587-91. PubMed ID: 7083151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelioration of vincristine neurotoxicity by glutamic acid.
    Jackson DV; Wells HB; Atkins JN; Zekan PJ; White DR; Richards F; Cruz JM; Muss HB
    Am J Med; 1988 Jun; 84(6):1016-22. PubMed ID: 2897788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Treat Rep; 1985 May; 69(5):523-5. PubMed ID: 4005874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced toxicity and enhanced antitumor effects in mice of the ionophoric drug valinomycin when incorporated in liposomes.
    Daoud SS; Juliano RL
    Cancer Res; 1986 Nov; 46(11):5518-23. PubMed ID: 3756900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate ameliorates experimental vincristine neuropathy.
    Boyle FM; Wheeler HR; Shenfield GM
    J Pharmacol Exp Ther; 1996 Oct; 279(1):410-5. PubMed ID: 8859020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinblastine treatment of Hodgkin's disease. Selected observations of vinca alkaloid dose schedules in man and animals.
    Lenhard RE; Owens AH; Owellen RJ
    Johns Hopkins Med J; 1974 Apr; 134(4):211-7. PubMed ID: 4821134
    [No Abstract]   [Full Text] [Related]  

  • 11. In vivo antitumor activity of the bitter melon (Momordica charantia).
    Jilka C; Strifler B; Fortner GW; Hays EF; Takemoto DJ
    Cancer Res; 1983 Nov; 43(11):5151-5. PubMed ID: 6616452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models for the comparative assessment of neurotoxicity following repeated administration of vinca alkaloids.
    Todd GC; Griffing WJ; Gibson WR; Morton DM
    Cancer Treat Rep; 1979 Jan; 63(1):35-41. PubMed ID: 105807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells.
    Tsuruo T; Iida H; Kitatani Y; Yokota K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Oct; 44(10):4303-7. PubMed ID: 6467192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors.
    Boman NL; Masin D; Mayer LD; Cullis PR; Bally MB
    Cancer Res; 1994 Jun; 54(11):2830-3. PubMed ID: 8187061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inability of amphotericin B(Fungizone) or of sodium deoxycholate to alter natural drug resistance or sensitivity of transplanted murine leukemias.
    Ganu UK; Khandalekar DD; Gokhale SV
    Indian J Physiol Pharmacol; 1984; 28(1):21-6. PubMed ID: 6490126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of murine testicular leukemia.
    Hoots WK; Nelson JA
    Cancer Res; 1984 Jun; 44(6):2464-6. PubMed ID: 6722788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved tolerance of vincristine by glutamic acid. A preliminary report.
    Jackson DV; Pope EK; Case LD; Wells HB; White DR; Cooper MR; Caldwell RD; Black WR; Muss HB; Cruz JM
    J Neurooncol; 1984; 2(3):219-22. PubMed ID: 6150069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance studies on intraspecific hybridomas.
    Pályi I; Turi G; Szikla K; Dallmann L
    Arch Geschwulstforsch; 1981; 51(1):119-24. PubMed ID: 7259434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.